Loss of Disabled-2 Expression is an Early Event in Esophageal Squamous Tumorigenesis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Sep 30

PMID 17009406

Citations 28

Authors

Kumar Anupam

Chatopadhyay Tusharkant

Siddhartha Datta Gupta

Ralhan Ranju

Affiliations

Soon will be listed here.

Abstract

Aim: Disabled-2 (DAB2) is a candidate tumor-suppressor gene identified in ovarian cancer that negatively influences mitogenic signal transduction of growth factors and blocks ras activity. In a recent study, we observed down-regulation of DAB2 transcripts in ESCCs using cDNA microarrays. In the present study, we aimed to determine the clinical significance of loss of DAB2 protein in esophageal tumorigenesis, hypothesizing that DAB2 promoter hypermethylation-mediated gene silencing may account for loss of the protein.

Methods: DAB2 expression was analyzed by immunohistochemistry in 50 primary esophageal squamous cell carcinomas (ESCCs), 30 distinct hyperplasia, 15 dysplasia and 10 non-malignant esophageal tissues. To determine whether promoter hypermethylation contributes to loss of DAB2 expression in ESCCs, methylation status of DAB2 promoter was analyzed in DAB2 immuno-negative tumors using methylation-specific PCR.

Results: Loss of DAB2 protein was observed in 5/30 (17%) hyperplasia, 10/15 (67%) dysplasia and 34/50 (68%) ESCCs. Significant loss of DAB2 protein was observed from esophageal normal mucosa to hyperplasia, dysplasia and invasive cancer (P(trend) < 0.001). Promoter hypermethylation of DAB2 was observed in 2 of 10 (20%) DAB2 immuno-negative ESCCs.

Conclusion: Loss of DAB2 protein expression occurs in early pre-neoplastic stages of development of esophageal cancer and is sustained down the tumorigenic pathway. Infrequent DAB2 promoter methylation in ESCCs suggests that epigenetic gene silencing is only one of the mechanisms causing loss of DAB2 expression in ESCCs.

Citing Articles

Identification of the role of DAB2 and CXCL8 in uterine spiral artery remodeling in early-onset preeclampsia.

Liu Y, Du L, Gu S, Liang J, Huang M, Huang L Cell Mol Life Sci. 2024; 81(1):180.

PMID: 38613672 PMC: 11016014. DOI: 10.1007/s00018-024-05212-4.

Disable 2, A Versatile Tissue Matrix Multifunctional Scaffold Protein with Multifaceted Signaling: Unveiling Role in Breast Cancer for Therapeutic Revolution.

Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M Cell Biochem Biophys. 2024; 82(2):501-520.

PMID: 38594547 DOI: 10.1007/s12013-024-01261-5.

Identification and Validation of a Prognostic Signature Based on Methylation Profiles and Methylation-Driven Gene as a Prognostic Biomarker in Differentiated Thyroid Carcinoma.

Ju G, Zhang L, Guo W, Wang H, Zhang X, Mu Z Dis Markers. 2023; 2022:1686316.

PMID: 37223105 PMC: 10202610. DOI: 10.1155/2022/1686316.

Disabled-2 (): A Key Regulator of Anti- and Pro-Tumorigenic Pathways.

Price Z, Lokman N, Yoshihara M, Kajiyama H, Oehler M, Ricciardelli C Int J Mol Sci. 2023; 24(1).

PMID: 36614139 PMC: 9821069. DOI: 10.3390/ijms24010696.

DAB2 suppresses gastric cancer migration by regulating the Wnt/β-catenin and Hippo-YAP signaling pathways.

Wang H, Dong S, Liu Y, Ma F, Fang J, Zhang W Transl Cancer Res. 2022; 9(2):1174-1184.

PMID: 35117462 PMC: 8798574. DOI: 10.21037/tcr.2019.12.96.

References

Mok S, Chan W, Wong K, Cheung K, Lau C, Ng S . DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 1998; 16(18):2381-7. DOI: 10.1038/sj.onc.1201769. View

Roland I, Yang W, Yang D, Daly M, Ozols R, Hamilton T . Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 2003; 98(12):2607-23. DOI: 10.1002/cncr.11847. View

Malkan G, Mohandas K . Epidemiology of digestive cancers in India. I. General principles and esophageal cancer. Indian J Gastroenterol. 1997; 16(3):98-102. View

Xu X, Yang W, Jackowski S, Rock C . Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem. 1995; 270(23):14184-91. DOI: 10.1074/jbc.270.23.14184. View

Wang Z, Tseng C, Pong R, Chen H, McConnell J, Navone N . The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002; 277(15):12622-31. DOI: 10.1074/jbc.M110568200. View

Capo-Chichi C, Smith E, Yang D, Roland I, Vanderveer L, Cohen C . Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer. 2002; 95(8):1802-15. DOI: 10.1002/cncr.10870. View

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

Sun W, Smith E, Cohen C, Sheng Z, Xu X . Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene. 2000; 19(42):4847-54. DOI: 10.1038/sj.onc.1203853. View

Fulop V, Colitti C, Genest D, Berkowitz R, Yiu G, Ng S . DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene. 1998; 17(4):419-24. DOI: 10.1038/sj.onc.1201955. View

10.

Ruoslahti E, Reed J . Anchorage dependence, integrins, and apoptosis. Cell. 1994; 77(4):477-8. DOI: 10.1016/0092-8674(94)90209-7. View

11.

Hocevar B, Smine A, Xu X, Howe P . The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 2001; 20(11):2789-801. PMC: 125498. DOI: 10.1093/emboj/20.11.2789. View

12.

Boudreau N, Sympson C, Werb Z, Bissell M . Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science. 1995; 267(5199):891-3. PMC: 3004777. DOI: 10.1126/science.7531366. View

13.

Nayar D, Kapil U, Joshi Y, Sundaram K, Srivastava S, Shukla N . Nutritional risk factors in esophageal cancer. J Assoc Physicians India. 2001; 48(8):781-7. View

14.

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

15.

Zhou J, Hernandez G, Tu S, Scholes J, Chen H, Tseng C . Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. Cancer Res. 2005; 65(14):6089-96. DOI: 10.1158/0008-5472.CAN-04-3672. View

16.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

17.

Zhoul J, Hernandez G, Tu S, Huang C, Tseng C, Hsieh J . The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 2005; 65(21):9906-13. DOI: 10.1158/0008-5472.CAN-05-1481. View

18.

Tseng C, Ely B, Pong R, Wang Z, Zhou J, Hsieh J . The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem. 1999; 274(45):31981-6. DOI: 10.1074/jbc.274.45.31981. View

19.

Wang S, Makino K, Xia W, Kim J, Im S, Peng H . DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene. 2001; 20(47):6960-4. DOI: 10.1038/sj.onc.1204873. View

20.

Montesano R, Hollstein M, Hainaut P . Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996; 69(3):225-35. DOI: 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6. View